ࡱ> '` &bjbjLULU  j.?.? 84 P !ap ```````$ bhud`"``p``d n |``0!a;e|;e;eN``|d!a8 8  Manufacturing and Quality Problems in Pharmaceutical Manufacturing Richard Soltero, Ph.D. Bruce Rehlaender, Ph.D. PharmaDirections, Inc. Improving quality and manufacturing of pharmaceuticals Improvement in any area requires an evolution in processes and thinking. While the rate at which most technology is evolving is akin to a fish going to sleep at night and waking up with two opposable thumbs, pharmaceutical manufacturing is more like a sea sponge that rooted a few millennia ago and still hasnt woken up, it is still a sea sponge and not the hamburger-flipping cartoon variety. For us, the cutting of trees to allow manufacture of pharmaceutical products has long seemed archaic, and we have invested a large chunk of time and money into generating a system that uses recyclable silicon instead. In trying to convince the Pharma world that it really is time to move on, we wanted to obtain as unbiased a view as possible of the advantages and disadvantages of sticking to paper. With all our decades of frustrations, we know why we hate paper batch records, but we wanted to see what factors led others to the greatest despair, so we asked 185 expert users in the pharmaceutical industry to complete a five question survey. One of our questions was What have been the most serious production problems you have experienced in paper-based pharmaceutical manufacturing? A big problem with paper-based manufacturing is paper It surprised us little that most of the problems cited by our respondents were related directly to the fact that batch records are on paper. One key complaint was the frustrating slowness of paper. Review and approval of changes to either a master document or an executed copy are slug-like, as the single copy must travel from one desk to the next, often finding itself lost in a stack of other papers like a Kleenex inadvertently left in a library book. Just about all of us who have ever manufactured a First-in-Man batch know what it is like to wait around in our best fashion Tyvek because the last reviewer found a typo on page 57 and now someone needs do an intra-building decathlon, sprinting from computer to printer to Manufacturing to QC to QA to Documentation before the blessed papers can enter Class 10,000 space and the real work can begin. A surprising issue brought up by some respondents was safety. It was noted that paper batch records carry a risk to reviewers beyond paper cuts if the batch record has been used to manufacture a highly potent or cytotoxic product. Extraordinary measures are in place to protect personnel during such manufacturing, but batch records are typically exposed to whatever falls on them and cannot be readily decontaminated. Those of us who came of age in the era of typewriters and fountain pens can attribute a percentage of our grey or absent hairs to some of the other frustrations that were cited by our survey respondents. For example, records can be irretrievably damaged, such as when an operator experimentally determines that 70% ethanol is a very good solvent for the ink he was using or a reviewer gets startled while precariously holding his fifth cup of Starbucks. And we all know that people who fill out batch records are masters of fitting lots of handwriting into tiny spaces but few are very good at making it legible. Documentation of errors, deviations, and abnormalities can quickly become a nightmare jungle of arrows and asterisks and dated initials suitable for transfer to the head of a pin. Additionally cited were the normal issues surrounding printing, accumulation of paper, missing paper attachments, illegible photocopies and scans, etc. Unclear communication is a fundamental problem While none of our respondents professed a love of paper, most attributed the majority of manufacturing and quality problems to human error and poor communication. Many problems occur because instructions, verbal or written, are unclear or misunderstood. Simple things like typographical errors can change the meaning of instructions, and what is crystal clear to one person may be river mud to another. Many batch records are simply not written well and, in part because change is so difficult, problems are ignored until a quality issue rears its ugly head. Another related issue is poor communication between sales and production. Often a discrepancy between actual or current capacity and assumed capacity can cause commitments to be missed. When manufacturing schedules live on a whiteboard, paper calendar, or even an Excel spreadsheet your chance of finding up-to-date availability is sometimes iffy at best. An electronic system that keeps a single, real-time schedule with alerts and notices for errors in human scheduling greatly reduce the risk of running out of resources or capacity. Key improvements can be made within the paper-based systems Poor communication and poor training can happen whether documented by pigment particles adhered to cellulose fibers or by atomic-level changes in silicon. Addressing pharmaceutical manufacturing problems can start at the source with the manufacturing personnel. Recruiting, training and supporting good, competent and qualified people is the starting point. Next is improving lines of communication between all levels and all disciplines in the facility and providing visibility to key information and decisions. Needles to say, much of this is exactly what we have been talking about for years and would have implemented years ago if reality didnt keep getting in the way. How silicon can help An electronic batch record cannot make operators more careful or production managers better writers, but it does address many of the faults of the paper system. For example, because failsafe controls and the ability to make rapid changes can be integrated into the system, the propensity for errors and miscommunications can be significantly reduced. Since the batch record can be viewed simultaneously by numerous on-site and off-site personnel, deviations can be addressed in real time, and review can occur concurrently rather than sequentially. Many types of errors, such as using incorrect lots of materials or ignoring out-of-spec in-process results can be controlled, since raw material inventory and electronic data are incorporated into the system. If a step requires QA approval or an in-spec test result, an operator can be blocked from proceeding until the necessary measures are taken. Most importantly, entries are kept legible, and you just cant spill coffee or solvent on an electronic record. About PharmaDirections  HYPERLINK "http://www.pharmadirections.com" PharmaDirections offers the highest level of scientific and management expertise to transform new technologies into successful drug products. They are a consulting and  HYPERLINK "http://www.pharmadirections.com/project-management" project management company with a unique approach to managing  HYPERLINK "http://www.pharmadirections.com/preclinicalo" preclinical,  HYPERLINK "http://www.pharmadirections.com/chemistry-manufacturing-controls" CMC and  HYPERLINK "http://www.pharmadirections.com/regulatory" regulatory affairs programs. They provide  HYPERLINK "http://www.pharmadirections.com/strategic-planning" strategic planning then oversee and direct the pharmaceutical  HYPERLINK "http://www.pharmadirections.com/cro-cmo-management" contract research using their own  HYPERLINK "http://www.pharmadirections.com/pharmadirectnet" scientific experts and project managers at partner laboratories who are our sub-contractors. PharmaDirections is a comprehensive R&D resource for pharmaceutical and biotech companies who need more than just outsourcing of their API or drug product development and manufacturing.       BCDkj o +,Yco!!!"""&"'"""#ǿ}vh}_}v}vhOoh0JjhOohU hOohjhOohUhOoh5h0hr5 h`?hrh^?Lhr5 hNhrh(hr5 hr5hrh'hr5 hOohOo hOohIhIUhhrhIUh5CJ\aJhOo5CJ\aJhrhr5CJ\aJ$CD[si j XYZ!gdrgdOo $7$8$H$a$gdOo&&!!!&&&&&&&&&&&&&&&&&$a$gd 0gdOo#####A#B#|#}#~############$ $!$3$4$N$O$$$$$$$$%%%$%%%6%7%t%u%v%%%&&ֺ֬֞֐ւ{ hOohd.jehOohUjvhOohUjhOohUjhOohUjhOohUjhOohU hOohhOoh0JjhOohUjhOohU0&&&&&&&&&&&&&&& hOohd.jhIUhUmHnHuhIUhjNhIUhUh'djh'dU21h:pd./ =!"#p$% n5'̧zd$PNG  IHDRՓ-wZPLTE3fIDATx흉cc´k^00H$T%]k}{P#YSGQԻK@Q䖢(rKQ(rKQ(R(REn)REn)"En)"E[-E[-EQ䖢-EQ䖢(rKQ䖢(rKQ(rKQ(REn)R)c]s^ z#nem(.E sބfzPpˮN \z+nm+BQomDC\z'nM%7v#\z3nGvPqkyM(ꍸ4e"E=[.A~f(vܶt)LQǭz?n+QԻqۏp .E2EKQoǭ NQPpKQǭ<Pp{͊:'}XfAEQmb E"il+ɥWNXw2E"]hq)5<2\z9nJvrN^ۨJ Lkl26:%k+SKr+p'n˒q)5[f}ֈ[p)%lGQM6)ݸm-E(h| 8̞_j]. *ϜvWs,G7^ 'MW3R rWɿrQԫq86,9e)+(6k3ߔĖ^ۢZk =奢Wժ \VDG6|Vbx m,6cH^ۦ=uF3;KSKQm ;5n'X^r?yT~2ER[z/n{p[6&w1EQ-WSq"R~Rqhn)m /E㖓@N܎Y䖢މQRqkxM(e=z;n5)꽸5?,Gz#n 5-/ E][z/n1Ėދat˲fܚRԛq-ER;qklh3^ zn,UBy.VQ#;|[ϑ/E>o )`V6pE6VR +S+s ߱.E0ޚtVh6ʲWReP^i6GQ/me-{PԋrOzQnseE.es^q6ln{nlBBQɭո-KC?^[-2.EQmo9DQɭWLPvVyv>,K9Rԫr[;߻^ۮ*_*_-E.)ꕹbf.7X^_/B,^Rԫs\q0.-E>]6&vm&V5뢖 mk^|nǹVƼK Cv+Un3M4-i{)ꓹmq;Ygl8֘d́!)#S2F[MQԧsz4~ x)) o1 ݧA5E}Z~Y̻=̌IQpkM?^>i܊G-/&E}:0~Cdp,Sԧr; SCRA'k,LQ_-lT#{.E}:^MzEn=M(˸EAB^M*najnm7^N"nA@y,qά *n Qԗq봈ra!eN$Uj]Vn{r6PWp;8ag78ĥOග4㯛>^ګS>ĭfftn_DrjDz6yFc2†%(m.vYW՘e=smU[NW9=fz0xSpm4qKrgPӸVCTO1b8(\SngvndV\c_E4GxWK~:Wv5_WQjfKemfV[ 1pe#!mtj}R[}ydE=aJɃ­-vQޢC06EQO䶆@6H܎4E=NKs,&敚In)SY4%Avr "V!-ɇBGøE=[-α[Q3[)9CQSzۀe/LQOvtk[ zuu/ p&[޽fz2E=qp<޺5n0B~2]16Ģp,B4fŽLQm>kR'vźMk(3kѪfqXu,X>[϶]Z 8s˰E}oO^ ʋ꺞ϱ;E=* Wι`u/6˼et-{|mWoHvr}3՗>Ai\dQ#gۤǸhh]8y.ifzKR[ۃyu/ϡivUZbW'RCԵ;`ql#!WS{^`; 3l*k=5:u=U =5g>E큅XMQH( KQ܎aAw*6P&p6$fwh_Rg۹+t%-pFǗ2 Eɭ}[-E=ۨr dj-'p;M~:RԽ/A?iRԃVZ9mO.jU&0Cv]-wm*jE0-oE=ȭGHyS*jsaE=ʭm55wj~rm"yzn2E=̭jzťM:UVROVs{1u]dRSUZ<2Ėn綜4TUg"Yj4^lwh07i,c}ME=HP|:#CD}PQci!a%ͺܟ:`Y jƶeIŐET * Jb`Vd)oݴ+Ju/U;t[h̥؛ S_M*^gy/}UZAoöi72n5G3ŝo%'q;(s)kqrkQ'r1FϿ3DQ㶻Zm +/WQZE /_]\bDQ Yo?NRuS-hma}J_Re^ߺmRks)zۮ5ZT$yX_W?sɭ^VֲE=!k{F5,!0 r Ϧ9 u̓ u/vZ0l6*zy]0bdm}7jrKQSJT~䖢["vܶO.E=[=.5, B MrQE= r&Llf2E=[=blGQOv$H,u..5[z [Ҭȭ ny%ǑZRӸdeݼ+elۖP33waŚuE1lK@Qv6]_V-@qm^T5!ۀkj-E=[_Z$?,'q[dn6a5{1f +ܼ.!Y`.z .1k, maܴC_/ism?SZ+ k{S]SL:\ƿ[!qf[#T1Gƽc y@B|ufm?c>HQͮrܻp6 (.n ) RƲl*am]((;+O|5xЅDNft)nu\.790wCCP:G<^q)nnyH5BŖW^j z[mJ}DBcUnX R܂ns[JvĝR܂V>y47Y79WLn)n+v  s-E=-V[w6N[z[d5=^-_ [`4q{Sk暱J+EAaֹmyL6EQinQ1ˀ Ru1WQ*Ǒ­qhˢ ppx(AnA : ?T:q[6Pԃc:i< {vG6 Iovn ړRtzՕ&/al\m֛+oN~sNX7qu ܦ)u`7s^'s=VXv9qxN￁A&`jܙ̳U+# sH'1%)<0][ ]d?P뺣 C.n{ i [_T\O.HɧI lnh3*mjow#=4EFmwd[='p@pyȧV@v>enEwubphuY۹n:¡]Dt՞œwA (j<}lg㔮{jpowiRƷS=1[S#@9"9}voNIrSu/ n[ca츝seu=7_]oѭdg\6 }8n0ָy0ioߠ#v^g/od͇9툐jp˲4ޢo_Ny滏!nqQtDsKQ"A E_"nܲ E%6Chmktn aPz#_[LnD5q)"nNݥvI;,bp9-_ۮ2JZvX[ i'uz<#f2]ȵ.Ja# I<ӁBn/)Nn=ڲ5O?nO?[ͩ|%NswŮnOAVN7OP* 2Pa< 'PrY v=(_$.\#ԫu 78;tp]cWj[aЯ۹ħm BM "T)ŶVza*vO4ΊJ]I7!n)U+2|7-HvD1MH:NN.vk3vҋHtʻN~e7y"u>WL{%s{A{_̕F'u%:^.ŝU?`B#-zPN֡\tn;-,DNꛞ:2sZg!in5oK=qTZRiMbxI@$nx= ۪ʼs/lc!.(|BpY!8innwY'Ot+n5㣗MT|ٽ1ލ#|J324 0U.z`pG_hC]ƌUyµ^M/0-=4R2;HTKݥ־SA;*abL?qScluۣ/ `TTaۧzˠpKe#q5̭4u_/lVT>}EaI'm,*jf[!bIoԎ=7>' n%~MUnz[5bSz`ܰO<*pOk)ŒvӴ`f6_vo_?5Wvs~l?ZY5DSy`k-2q~z??K{GE}ћǽ+].+0KQQnSm=H6H#gXo`Z6( r;&BLY6ڒs;([o@QTn幱ک/[whDQOv Z4zcO6,!EQq(ܪG.ZEQ@T).g1N$`oCE iny(y/(S#BƯ@xyhʆ)z"#c+-E=۬[s۔)AnkM7׸e\V͘t[@|@ E[HEooz[`63hɶ,m5:-\~_h2E=έ1_?o:(,39( 4,E;75dc;iE=v-d[ɀ]7޾ + B鳙WAfJkKQpk֭+"|jY5A֙d[q]^ f05hPW_o]gJs}Ն%3XͶZVYVu.ȣa7v=?͕峑W=WaJ*~,n|3 ֞k(*`6$"K6Gx7 Zu2 .#vgMr+DФO5rfdPT[jg1ېPusg\v7ݵ,.¯mO(܎V ?hla[8MI"ΤCR>6JPvN4-.4zb[tޚ [bE6WKAh[#GǟF8KQvV 0R-nYk􋢒-v҆&U)F[m-֡TnEn ơ;HXuߜ $9 2[z[ϭE2e\.n[ĭ!VMZ]A*hA|0幄uPVyx( pfzG5s!iDcX|)BFĥ`Rb%n7R"r5;x XYRT[ڱ=7禎 5>斢ܪ &%[`YK-j/seIKl\'ǥ-E]e,'5y_W bۍZoYfK|eXEVni kLĎ2JZso)xC{*m^gc13~P|IrD]r/bZFv)磏gk yAJ2r-kޱ_P~un 8.vi i]= u>˦סPVOzP;y2mϫy?_}3w!=,P)n"O0Tdkc'q氱"Ք}cPøyx#..0j -s;CUCEu[/7=WekSkukgP:nKmgAwoƷ:C>ޭ2BaQi{s;w@mvDpdUV.?*/tr?Yv b񀟚]ZYcB[繎\-lMښ3=h/O3}uY*=[Kז=TZr{*y_Q]>#6ҽ2 Koc?#8fծYc1hp/hnjSuL_p<*,.+Ǿvl;cW𮄁z-˵kAnvOm#Gb }]]iuEv2 vͭ9ӼjrF]d GdǼ/#d} IY,uY?0W Tln1.(S(vKtR3knU0ޥ\#P g9tMrܚF}/no|J +{2o p 2U(׿ n -]OtS\Ii 9%eie]kS̠ޜV[BMs3a5 e=X "_ erۡJE}zsέ^mU%ZwDzֹTLh{Z`8-j`ݰ!{AD x|ED)84#UnϸmefZN9q"esom}ӷTnQUt#D?^hoxОf0ȗi L_ܢؙ<8,2)n+}uԈ[ؿ$۸b.,.-hTgw]wXxz* K:m8M} ;Ν ah8k@G݃)D::( Ķ2ۑ[m-Jܵ6%(S>ϸϘ>^nKm^TK/כtn@fxM153R՗I~C,5X(ve" H*ϳifSZ(9{wTg64 øF f2\qZm߼q7uAÊ|ыԬvkZ^ݗ0o;> ;~{n.zhwhcAXͦy65l:WeVGe[Sp k}ɮ;%_ Ֆr3B+[ n36GҊgE¸{݇VvESbiHgk6zŦE2|Q8#WHVw44UUe^mc@hu0Æ*ݛ !fгg8z-?Bi:xJumUyښwG9z C;x.W@yTǣC+u>=gb5<ǿ?6那h>va3=ul`2S4͘_x }V+a{l~|nwdyQ=ӖA׽.V:#f;ݶID/2luQoީ.7["vYov =z-joFÁ6ld7I/-cV6Ұk?YgӢV#M,皫5Xʶ%T*ȶ9!3b!-5S^؍/O>߉[#vh+ks&}`hYP740pi+ZĞ6f`^ryee% ~ '4o 9ԡL>fFmbmh]e?@oC\ V4*oyJh#` -zԱbuN*_ނ[p!&-@琛☁] Dql 3,-XR(xeƌG8!Քh|;~nѝsq`ml77$ʩnAA@ T=8Xp a-wnAȁ[\>Q<-*Tl"n}[ picnik.com ,IENDB`DyK yK Zhttp://www.pharmadirections.com/yX;H,]ą'cDyK yK ~http://www.pharmadirections.com/project-managementyX;H,]ą'cDyK yK rhttp://www.pharmadirections.com/preclinicaloyX;H,]ą'c DyK yK http://www.pharmadirections.com/chemistry-manufacturing-controlsyX;H,]ą'cDyK yK nhttp://www.pharmadirections.com/regulatoryyX;H,]ą'cDyK yK ~http://www.pharmadirections.com/strategic-planningyX;H,]ą'cDyK yK ~http://www.pharmadirections.com/cro-cmo-managementyX;H,]ą'cDyK yK xhttp://www.pharmadirections.com/pharmadirectnetyX;H,]ą'c-Dd5 ;;n  C JA2PDI_logo_RGB_PNG_subtextb*->V~8fR\On- n,>V~8fR\OnPNG  IHDR]PLTE###222[\^AAA^^^OOOdegyz|opq{{{mmmʼn:>FIRV^bknwz넆퐒*ZIDATxkcŢmUzT\!~kW$'d P(n\̨|[ PTf>Kk="(ԭu̴ܞH}β: (T]x&7"(TpX̴D5^X/$Y]D"Q n>+UgH$Z k~M$HT|DP!Dj\D5V_ "jN*DΖH$ ŬH$ 2D"Qԩ2"fjYȫJ"FD` AlDP"I"&j CfH$:ys+jPDcF"Hpj`@H$ UUk8"H$yZ mmE"Q -BUH$8!!(T5A6 i J$pT:$D؊D(vHT4C"Q($Dn@$B""D9BHK$g~D-(H$qk>D5NX"Hu^D"Q'(HT$A?G"Q,HT뵳A"QJD5P5"&V$D~Dsmwd!Fj]ND5S5$HT3ln;D5T+P"PkH$6H9nE"QptXH$ 59D5Wg3y$H I$H I$H I$p^W"k*0D5^:DPD ;\7 (TfDb\\$b:awuE"Q(Q0|H$> FO<6pp.ND9o/ =}%pm d]:gq|z jL0HԿׇL&v:mOH$q$5!w'$H+8*7$u=>j 64P@Od&g$uPH!S޻8!Ca ?_53>+h!Yo$g;$0 I$uO/")%H㡂>@| Dݟ~*2/gcYe$u7}F/dnS-7ya$&[iZb_EzEzӶ|I7ӻo1HCJY7O)fԱUYOE'<]0E엲\iwמM]./AM* r+Rz R=Η"__?|{ъLGb ? je[+b4{>nn2%  ?kV֤L_ |s( M@-su"ADFy猦/ F䃺}#z(? 2\jD8T#R{*4ȹ0(eٓu=h$)D?RH s0WI䣲[r+HEU$r6[+@vQjOmeHqnN2A#q 9ȇ_"sۧ遘 N2yD_^THyW"燄 2cQ( ވg®h˽m;t0ȱ2kD`@dYg"A<#R&Rk|!R=m\A "e2Dǜ ȜIQɵ%._AP7FuH;tgN`DI)A&#"~L-I`+g"?YD.TEz"7kBzZ-+x +a-/,"wb.=]IE./r֔O'P"D^ &UYD_ xU,3RREEt(F7)䄈IuɼtXj|d)T8;RK.Iͬ`ҩ&OIJIi{̠]įH'JgɧyiW!)&Yv,L$ $b(]H>KNEWNKi| oDna;ɓHn%SHb|> ~ t̤*/euS)vRD*/J$g\e*E$Lq>F5@XgM2S .~° >l0T"5޿3(,1#"O/V7qPH6O[%ril"<]JvH%}zd$ɦe|eW4ȟ"rJrP:?|eTK#yVkte]'Grs#r[ڿC ORO ԸdQ'2H3HRϏ\z"_Youh̷drDg9,ldNw̋ngYڏ  $%r@1>% DK?#-BO1s"rYE֘ȝlv' VL'YߟH~]g@Of:` _7k³N􅈜"\,H&sjTrB`CUc e&& n;k-D~HGez"?Da z"GMYD(B)Y͈~Q#3%JuzC&z(,[C"wD4n 7-rX?'2Xj; 6rfBDScҔ,)mEw+ kl=t`#"/ 8 d(D2T1߼Y3|љ~3ZQ䒰v%9UBDdW-{|LEvgҼYH:";Gy"_v_(¤U#LCk$rW}53"gEg{jAᒽDȹHflf';Y߅_.?#"2' U4 }s!"%<$I!"(rU풘:3?oQPQK)i$y YHrb/W ց ^Ez<7"YD&KTNٟF&<)ɇzyDc-kjMPDj0ܱ\?"DrGHMkT'(MGjV E^dZޒcVtyd“_yd>,h,5rr ^=QF|2H6ϖAZކ'+GyҙX:s5Ac$}I"ʧ-WR[kU.!8 &D*e{,̍?E$? ȼs ,?RY,F$kl4 L6]<#+9H`gԋKAo!ӛ|) &DuaX[G" >ȸ!1 R~9"ט^Cs{4g=$2y}5#<Ωس*EdvFW6Ύrsk@2Bՠ jڰs"qs޺7=Wy ]Z"[b=]mPH> )#]tDtH<}{9RJ2cf, p" Bx&@H6}6]qݓGM%.5TY@qVres&2'l-gpD:^*Dd=ojW5,C>?oxE<턩:~ GHf N*)..e~6rUSeLs G$lLsW!5) #@.]$;.Ƚ9cfMt\ۖ$R2~n'wQ{H)MGC(<ذkeɢK ʼnq;e~a;Yo p}dٳR?;]ʢ(0#HسB(Ȝ࣋!h :0`;4VM%Df#9WGK=%ZzDPsDZ @$1h}^.(RHna DG%JuB`QȬ3ܢ3)"}/mg@ He8"?FI %D=;ȥr|Mu _UJ5AѹV"4My=NtXOK2?9D~@:+^s(vHA"A^jv2#Rs6)Pօ*E@NvU|`ʌD>mP$^1ZQ"/Lne^mdD^׉b6+Xֹ2c"褖6HB-ė~M5:xks!L(`4CJYo唺L>Qc≧C԰h=f쳲=UrݝNAkV[`]Zac'}5 8 ;oqY*cV$uOyd^ΰsl΍DHI:I/K^h@ے ON/v$l<PyM Eյ@zΝ * "۲%c&=Nԯxc3QZ$k!?į=Kb xjhj:D4gQz8J zK lL^_ $zW,𖞐Gӽ:xG듸i=J3@4R>=嵇bl"jD^Uf+5v$"'{ABZKr!IQ<0}i+0U tq'D4v)v|\7̔JDZZ+b&r^p-Rj`[P/L($g%֔ N#+ˣiש_]?& V-cvt&ѾN<@sx]dZl萒o׍IP_9S|GE{^g $JȨ }niXŇMW1kS:ZEy-vfN,ΐ^ Yc\z<nhM N8V2.u~P{祎.komف 0;dʜȞ8lߑTj妱41`,<:{n17nLYsL<tgԎP K*:Dv7&$fT@uW73Cz9ny'iQp%CCן,;\)5'psU&/艶Î:βgIvHLϦD>ː%6P];TqmDqSy): ЖRp],C PDZAJՐ]Hђ=z ºd-GdGl{ZnOs.涐qS:Gn~Lە{!-f QII NRX.zKd⏛A"TT]gJ"}[G~[I 2u}YZM&ew\"}+m5tǝSdlX"(iq!*Bb8?+(L4eܴ딯.nBd~1wiu۵򫦆@JA=dRH:QV O@_Ghd)vy<ؗ|<[̸iUש_TqK\ ;9sgǢ[<-J/ "ǼjDWLX*tv)I$1$R/2H*"q*Ӽ:xL6r rYVI]j@fM_ԖZV@.Svm5Z쾌­$4T0w&jH\]d;rЬQQ4@5G^P2϶'~"2pI]}>Fl)~%㰰<L_{utu=N,׷VEC.ު#5ct 5wzfMd*ay~nyrrr#€-ZW7u MTUj#Aݝ2piGVpPj5_]ki]ވpPAӪ1u~u6!]!uY_]}u%r{#2XZvޯaXiG"OܮP.W\WWckع#IdҖ՟*_pojxu7^lDWY#S+j`B.a3DB!u%#]ec:yɼz.ee)S?Vս)mS2O?i61;ʜj3~rDXv@yS>l|lDSn,t4F-40z4T*ӶpIl25'ck*-D9 ;5SUV`A~8lx7#\%FŌEY&MCC' X_ΔdHWб-|& s@Z^ Ojc]aӐQWU1W`9u==.+0`&JN1H5ފ[|hDƑQj?_6s7'r(y(&c~)iJёldE͎judhB>j0ٗ,/ Rðiѡn$li ^p69 Lg`326nڧ&S_|LRE[a̦d̙(?'xq@66ا6)y\б`dCw=8S2wm@ƞ`:؉Dju_Cr@Ԗc؉&BcqWԼ9d\: Dcu {Nj/yn)ǬtI4?EDA}-ӊ6hYmƦH"7y54]IJU$N aMY4bٲ'-!'ZLruԕ x4SԢCα<'KnAz<?;1v%V00t?9w&~P ӷN( lmu[)%OZ9:xcpT@2 tY72?uxB;a/=5 ,v٥A ݴJ/5G@DAٌ#\OJ->Ec{tO QS~6+١4KW#n[) MF/(.0ŅEwH걓mtp\ƅӳTW눌nڥwؒEyT(ơBUԏ, ډьc6„T*(1fK8;&9diJum&^cWⴊN Hƨ>7Ur2ӓ,iħ;:s~rt;=6"`\"=%L-?y-Ns| v91=UGq_;(wuK2Ľn?&$鑰8LiTѻt5vRQԜ%^b 0cTKYЀd+G<)]$XOݘȮyJ")V㲿mvŽ )z%*Nm)E}eKİKyhbr07#+,SM %QW'`dlmsղ]䭉Tmnz4L@IҴJߑHcv?K11YI)d1VNF-V!oiOǪG6 İ3d֍ J>( ޷%qjEޘH*u >[9kTS[&A;&z-rw(r@1wneۉ9rKa(FI 甎Ot3L OlIdW nsӪ]䍉}o c:d@hy"F'FĽ uNK#QEl mH*{ á?\~ӗ;gZdb7=Pyu}0GSkD)HEn Z[| |u3 ^c>AӸ:ӍM9?2k,٢~zB#wI7ml lPӐHAyfa:VkH?R iwu9tbIR7dʮt5u["mE*bёl2DCBn$-ml#=;sd$ϟ .l۰q[\|ɂ,xdU*-0qx?MD1mķbŻ)/C204S+s3#GL42Q;N_6o\mܺN0?!-*[d h\- ,ns =+ \k 25BD_Ndn^cbdKnYhS7 ;;{1W1k]3 { U4˻zDCEkYYH*ԩA"QÕDP| (E&7gD̘H$ tͮ6@"Q(vښ?,H$ %|Xo4rnWqtEXtSoftwarepicnik.com!iTXtXML:com.adobe.xmp picnik.com ,IENDB`@@@ NormalCJ_HaJmH sH tH DA@D Default Paragraph FontRi@R  Table Normal4 l4a (k@(No ListB'B dComment ReferenceCJaJ<@< d Comment TextCJaJ@j@ dComment Subject5\H"H d Balloon TextCJOJQJ^JaJ4@24  0Header  !4 @B4  0Footer  !*W@Q* d.Strong5\4U@a4 d. Hyperlink >*ph4 CD[sij XYZ0000@0@00@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@000000@000@000@000@000@0@0@0@0H00 DsXY0000P}0000 00000000000000@0@00 #&&!&&&A} 3N$6uXXXXXXXXt  ,b$'̧zd$544@ 0(  B S  ?(  ~  S @A" PDI Footer Image"`t@UYD[ik!)33DsUY +-2:B"BMMP\_ua'*245+7]<=S@`NPVy^OR6eReh-wzK  '#|#% &'+5Z6(DFJPVoq1rFL $I-L0@NO^0`w`l&# r 0$o]8!-/Q4TZ3\a gklmCq    mG &L' )&)*0:6!;FHHOQlx{8   L S"6X=AEIJhn 5  ! % - 2 5 N? F S eW \ ^ o zs x   -   ; P! # {/ 7 G P \[ u] 'b ?b k s tt { w    ! % 0 6 N ] 2e u } 8 Q  o d    ) + 9 mE F K M b `f k m Zp jr Nx x g{ }   4  3  / A G X _ !g  bt sK 6!$u(-1:=?QZbaes~~=B""#36Pdjmu$z{\v%&=NDP+[_E`be  !02j>0A,RBT}Z\anotcvovv{Y2*,-$2@55Fs\e fCfkfBhjw{K6!z"O#3&A/3<D_1beYh&lx4{ }~ gh%%I2Y3<>S?JEKLM []irr4"/9:;2BOGKyPXS_"q1?&L(,6D4EL3PTTUWc gVqq j'45AAHUUW_`j{~c+Y.UDG(WWY,cgghpzN _#.$,&/7:O;Mj\]d_`d+glrv]M0#h%O)+N25[>*?9ACWXbjo+ p !b+ ,.:?ORkpry J%6)9<BCKNAZ7ace'h]K'+z69;>@ DGOlS`nVt|<Zo(5Z:p:)<JIQtQVZ]bq.uyy^_  &?'W4,6KPQnWV]^` kq _ % 3 W4 4 B YG h_ Uf iv !^! !!!L!%!)!8-!Z-!1!76!nC!C!E!aG!H!T!^!l^!"b!Nc!m!q!u!aw!}!"" " "s"""C"F"]"u"" ##i#5*#-#1#7#9#:#?#C#E#?F#N#T#]#]#c#g#h#Kj#k#w#x#~#)#]$ $)$$$$-$7$F$2M$$N$}O$dT$Z$W]$k$l$no$o$u$Nv$y$%K%P-%A%D%J%Q%wU%l^%6(8=(>(G(U(a(l(l(p(tq(w({(>|()')) ) ) ))_))a)) )[ )X,)]R)C[)$`)@g)|o)r)s)v)|)Z*X*r*(*k;*J?*E*#N*-R*S*X*\*c*p*z*{*6++++g+x+&'+o,+O4+R8+:++@+:G+V+kW+X+z]+%s+x+,,,,,L",+,J,K,PV,b`,c,1g,=s,@~,-j--0-}-2-K8-G-P-9c-m-_p-W.0..h.. ".e%.F&.(.(. <.<.A@.tE.!G.G.GX.Y./E//F//7/9/9/M/O/dT/]/`/b/k/Pr/s/=}/| 0 00*0,0M0a0 b0k0p0 y01f 1 1d 1B11v 1d'1+1I.191z;16I1+N1N1EU1_1i1k1p1)y1g|1 222s22222+222:2@2@2E2I25O2W2o2r2w2'{223n3:,3-3./3tC3QD3L3M3O3kR34S36?6A6vS6X6hd6 h6i6Uj6Eo6p6q6gs6iy6z6~66[6$77 77o7w777787{#7X1757A7G7O7P77m7p7w7w7{7|7y888,81898:8<8Y8e8t8x87~8R9 99!99{9w9B9;9[>9tF9O9V9j9k9|9|9~9?:e::: ::$:&:6:?:&G:I:K:N:T:uY:m:m:n:7p:v:y:z:z:z:;&;;;;;;%;&; );0;kC;rC;WF;G;LO;P;5T;[;5g;n;p;=y;~;< <_<2<<#&<2<6<6<^>< @<E<I<N<=Q<=S<>T<NZ<Wd<e<g<Dh<Nu<~<8=/== =4%=)=7=C=L=bP=5Z= ^=ie=1f=p=N>>&>,>&/>l5>@8> M>M>M>TT>DW>b>j>>G?J????? ? ?5&?(?,?1?5?B?F?H?`?+d?>d?f?f?l?l?|p?s?Ox?v{?@ @@@}@@@"B@B@cE@"I@P@hR@^Y@Om@o@A7AAA#!A"A#A])A0AFAHAMAYAnZAiAnAoApBB2B B"BEByNBOBfBiB'nBuvB^CCGCC%C&C)C6Cd7CBCDCHCJCWC3dCBhCoCrCCDoD]DtDZD$D+DA>D@DUD]DG`DnDEE6%EK)E0EB=ER>EBEOE9REREUEYEKZES]E^EcEfEjEnEcqE FbFkF#F#Ft%Fn,F.F ?F CFGF~LF#MFYFhF) GZGGG G"G)G,G5G9Gw=G>G6FG>HGkMGSGVGWGdGnnGgvG#HXHyHH HHxH"H*H!,H-HV1H?3HD6H7H=HDHBFHFHYHeHBhHoHsHuH|I`II I"II!I3"I&I-I/IWOdOdoOpO~OPPPjP P{PP#P-P9P:PCPGPPPRPZPfPiPoPtPvPyPsP QQbQpQQQQQ$Q%Q*Qo/Q9Q?GQbQ{eQ gQo{QQ RH R R7RR0R!R8R:RCRXRMbRjRlRLsR{R~RR5SyS:S6+S,S7S8Sr@S"BSDSJWSYSyZSiS|lSlSnSpSkST(T-T1T;TYAYBDYGYQYRYYYZYv]Y`YdYfYyYZAZ ZZyZ,!Z:&Z91Z.6Z<>Z?ZGZ,MZXNZbPZSZ[ZhZjZkZmZpZtZe[[ [) [[[[!["[#[J&[9[6:[@[F[L[Y[g[\@ \\Q\!\X*\/\0\0\r3\Q5\9\?\E\E\R\=[\p\w\|\|\]8 ]]]]!]&]J(].]"6] 9]C]f]o]w]^^^!^}C^J^K^rS^kV^;[^_^c^h^7j^m^_H__!_L(_/_33_4_s7_8_9_<_A_WI_J_dS_g_i_-j_m_v_}_d`(`L``J/`7`C`+D`J`O`LW`[` a`c`s`L{`?aeaC aaaSa"aL&a(a9a:aTKaKa QaZaIeavaJ~abLbbbo,bZGbIbDJbJbUb:WbjbmbTqbqbvb}bcc cc cf%c?cEcMc?PcWcbc&gcmcncr{cdd'd?d0d3d?dFdHdVd0idldvmd{d}d~dweN eHeee&eX-eEeJe'KeOe9OeRe-WemenesewefVffMfff2#fAfVf]f]fX`f`faf)hfOufuf yf4g?gggghg*g4g8g:g;g=g>g?gJgTgYg`gigkgrgwgYxg_yg}yghhhah"h.h1h7h7hP?hDhEhFhIUh|_hechjhnhii izi .i~9ioOo8qo*rop ppYpp!p"pm9p<>p>p@pFpFpVp,dpqptp/yp:qqqq)q,q3q5qK7q7q8q9q;qCqPqfRqUqZq'^qaq{r~rJrrV#r&rV(r/rV2rw{A{BC{F{G{+M{S{[X{m{|| |||p||X"|=&| )|*|4|@|K|P|v|}-}C3}4}7}8}=}&>}?}X}Ek}~Z~G~$~)~:~=~F~iL~S~W~c~ud~s~c~~. Y  < (*/8GPwPQ\{jq?y;z~w$.I/1_255E@DE#GG[J*O(c:g.h_hm &/2S3IMN/U'VZx=w #$%q(47+:V=?rChNpYSa2xyu{:Ey (3,.9.B4ILeXRfgDgk{pSrrvv\}~}~@D'-.(46:;x>KB[_ `i5m!@=DHKNO]SIW]`lg= $w%(/4;<sDDmTVe5rsz{ !'B()b,T0+2}345@7FM%Yg_jjkmuvv{5~~^ $!BF#GGKM{QT[mflzhcnJd'.38%<@Bs__!lm)|-% 2 ,I%-6@B?CBELM3PXw[3dde j~kno  "#U'1:Q:e:\QT?UZmj?ry~ Y= ,K-.BC6EKQ``cfi4lpsBC xK*-79B:';n>?BCCGu_=bvqGw7*537NdZ]cee]j'm7vv|mZ ";a"T*-!15k9;:<.A0CDkkrwv~#|*/48~NSV\\an%v|cR"-P005={BHTNCQQRIXYrt} B-;?HMM[uefkrrz}cG$)\* U\qswyz}O ( qC%%I*04@C9HHMPYZ"\olo@sxfB**"*-3<M^|cdg|@-0R59<ARS{[bbNejQuw)yt P )|)*,16:p;S[]KeEfggWkqyU^N @Kd#',1?@kFqH6KWXX[\xx 0")G,."/33 44'6l=>OEM.j0louZTc &%F+EIw{#*,/0n9@dACTTX_gcllCms&z Ci? H1^4AEIUNXXkZZ|]~kk/luxM4.^18F;ANB X eghAs[~!(0<=BDG%HU`Badepjn{k S"# %^,W7@@M]^VaiMl]lmay x##)\a,bfCii}u yW<B,04P9u9?fL}VQW\^a@rz # )-89?A5QCGKQNR"SUUY~h-nxnrx&G%')7:KxLRREY[kth#1.9=G=B4F"OO}qXn |&'$)78=?zKNN7_bk] %M&34469{=-BEJKOPoQ&SYiZ[\fktm/ `+125LNNGQXY< a (~+166;rBK^aclopZz+}r #$".58FO[`j lAmorx.X#)E.J:rEFH$P QNQ\bm{ryUIQ!K#478=?BCIYbc$n}p#|)/4q=B+RMReXXZ[_Rs`xC4'n--0{59EeNDPT4ZfgqrC5+#5k6<AC`hVp GMVHgEk9wg  & );>BKCNQRT ]l+mq"stxyyJ~, s ), .u33f:LN=SUZ^aaoj8ksu|e+ }  !y.26@CJEI+OGPQ__c?y| ~ Vj] S'.)t))+;.R0>4:<(>=DERRWlZt=SrGJ"c37~@SAjBFRbTG^hl qzh`!o!#'t--[68ADE9FFQGO:U3X[^O^%fg!n-yy }w/ "(0a348;N=9JKM|OOsU]fg"mrs1z|}9v !)&8J@CiH\`hbcxi4\ 29AIDzI8P RT mp>{{~X !'?IOO\9dHdfz"#<.0>?aghWhDllmn0tx|z^ "$(),++/&7:?@C(D9ErLVa_8awa@ehhilqK| V!L!(2)e4?vFX\k\]Jdt2z_[ **-04y45168??oGKgMlOOQWWY#[]g}0 Q I!(..]337CHEGcPQW`egB 5  T+28SIJN[\]ddeq&yy JQ, 2X8$LMNPOW[ \^dkknqbtuw|g *F/GOT[`]aadiWoq8sh[ "~>'e,r7[BEW4X\|`afksu)w CqH"-.1)3B358>nSUYZ[^chq{  &(18Y=WlJnPz{0}<  'V234SV~WX`e gvxW %(5))>EmJKDR]w```f|} 0*-.0#Zb !'k.\/< =AhIJHWb-gThtvy}` _eJ!s.\/}BKGLUY_]_1a!fksuz  +,/i5:#?AIO\^gc>eqy|} bq>DFQc`na [a"5%&$3}9#>@VHKRT]bioIszn{u 6 "']* 1C18 @BN [bg]nn~2 p#&&+7":;=1E\HWj&yza %N& 3;;Ua,bbbp)q|$"S*7v8:ABCdGM#NOS]^^`*epnrWv!L$],k8ADEGQJOOQQQR'Yknp  %,.p/5JEX_-` hmoz4|Z|_ n'..71+2:7<kGzHILQX`Kce%mmst`w@ )!!%[&c0278=AN,PFT>WhWX_R`4vv Y~4""+,..35=FxJORpUV]` f)g# )+07F<=>]`hlr}((+,u-d.5JbMP;^eNg pZprAt B #(*+ 1?iATcjr"vwNW$%*5-m2V?@~CJOWn\x_de2msCq#&'-\09EHY`cBcQuz|! !o&<1q;RJ Qmq3r:r  ),/<>9BLUYN`dyi$s{}u Hc!J%'8=HTcbg,il-v| /D#$$%l'd(f(!*04<=X?0FLORHVVy_`egjRknAux|N~$zp  !#B-V-}8=<B~FO RY2__9bghin9z(\a9"y$=*11.4?C)Nk?DNTUc llsophr|y}\ \$*+g2 7U88&99AoLgR#ZQbdhCnftty#$$u%(XBCELHH8RU`j(}fd2: c%1 >L@uEE:FDPPTY[]acow"z|  3&')+5w8=<FWU^`aimVrw~ h_!)u-,.0[GJamQtxz}Nb<&V()+0T7;GbIKacqhrtvQ6~-3;e?Oadpu>xz}x>/2K4<x?)DLKNjOOnVN_cHcde`kpg : a#B./3x7:%=/>HD ]glp[s|#K,30FtINPRVW5]|h nu k;4$?kC%GR?\`Lhkoiy|}AQ$$'-)04>CFH]j2u/w}v 5Wr!8_JWWd `aE"s48<Y@+DMWC[b5cgnjjs{|~ ! } [/5;<<EOP^[`dE .1NT8XQgkp#yix"%{().139N;=7>NX\_aghpf}"m%/1@@OGGJKKWMMRPWYaefuwy}^ .+5:[;DDfgy -i(*57;>BEeGXUYYZ[bcz $&&0D1XCNNOSs]dnggSl, +http://www.pharmadirections.com/regulatory% MU Ahttp://www.pharmadirections.com/chemistry-manufacturing-controls% YT-http://www.pharmadirections.com/preclinicalo% (i3http://www.pharmadirections.com/project-management% AK!http://www.pharmadirections.com/%   !"#$%&'()*+,-./012345789:;<=>?@ABCDEFGHIJKLMNOPRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry FgnData 6:51TableQ;eWordDocument jSummaryInformation(DocumentSummaryInformation8CompObjq  FMicrosoft Office Word Document MSWordDocWord.Document.89q